Invention Grant
- Patent Title: Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
-
Application No.: US16865512Application Date: 2020-05-04
-
Publication No.: US11292796B2Publication Date: 2022-04-05
- Inventor: Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
- Applicant: SIGNAL PHARMACEUTICALS, LLC
- Applicant Address: US CA San Diego
- Assignee: SIGNAL PHARMACEUTICALS, LLC
- Current Assignee: SIGNAL PHARMACEUTICALS, LLC
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D498/14 ; C07D241/20 ; C07D471/04 ; C07D471/14 ; C07D487/10 ; C07D487/14
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2022/04/05/US11292796B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III) with a compound of the following formula: R1-Y, in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R4, Y, the palladium catalyst and the base are as defined herein.
Public/Granted literature
Information query